A press release from California Trim Clinic, a physician-led medical weight-loss and wellness practice, introduces what it calls the Hollywood Glow Stack, an educational concept built around tirzepatide, NAD+ and a trio of investigational peptides. The clinic says the concept is not an FDA-approved or clinically validated combination treatment, and it repeats that point more than once.

The components break down this way. Tirzepatide is a prescription drug acting on two hormone pathways, GIP and GLP-1, to help regulate appetite and support weight loss and maintenance. NAD+, short for nicotinamide adenine dinucleotide, is a naturally occurring coenzyme central to cellular energy metabolism. The GLOW Blend is GHK-Cu, BPC-157 and TB-500, three peptides the release describes as investigational.

The celebrity hook

The framing leans on two names. The release points to a January 2026 ELLE interview in which Gwyneth Paltrow discussed her personal experience with NAD+ IV therapy and an NAD+ delivery pen, and to remarks from Hailey Bieber, originally published in Interview and later highlighted by ELLE, about her interest in copper peptides including GHK-Cu, and in BPC-157.

Neither woman is connected to the clinic. The release states plainly that celebrity references are editorial only and do not imply endorsement, affiliation or use of its services, which is a disclosure a lot of wellness marketing skips.

Where the evidence stops

This is the part worth reading twice. The clinic says NAD+ is biologically important but that clinical evidence for injectable NAD+ in anti-aging, cosmetic or longevity use remains limited, and that BPC-157 is investigational with insufficient human clinical evidence establishing safety and effectiveness for therapeutic use.

The GLOW Blend gets the same treatment: safety and effectiveness for proposed wellness and tissue-repair applications have not been established, in the release's own words, nor has the combination been established. Compounded tirzepatide, the release adds, is not FDA-approved and is subject to federal and state restrictions.

Bottom line

A clinic naming three unestablished compounds and then saying so in its own announcement is unusual, and it is the most useful thing in the document. What it does not change is that the celebrity interest driving this trend is running well ahead of the human data on every ingredient except the one that already has an approval.